Most investors carry a simple model: company gets funded, valuation climbs, share price follows. Broadly true, but a surface-level reading of something far messier. The timing matters. The quality of the investors matters. What the capital is being used for matters. And the gap between a round closing and any real change in the underlying business can be enormous.
If the jargon around funding rounds feels like a barrier, here is the plain version.
When a startup needs capital to grow, it raises money in stages, each named after the point in the company's journey. Think of it like building a house. Seed funding pays for the blueprint and land. Series A builds the foundation. Series B finishes the main structure. Series C and beyond furnishes the rooms and prepares for guests.
Each round involves new investors buying shares in exchange for cash. As the company proves itself at each stage, it commands a higher valuation, meaning investors pay more per share than in the round before. That rising valuation is what drives secondary market prices upward for people trading existing shares in the unlisted space.
The key thing to understand as a beginner: you are not buying a product on a shelf with a fixed price. You are buying a share of a private business whose price is set largely by what informed investors last agreed to pay. That last agreed price, the funding round valuation, is your anchor.
| Stage | Indicative Valuation | Focus | Signal |
| Seed | ₹10–50 Cr | Idea validation, MVP, founding team | Angel / micro-VC conviction |
| Series A | ₹100–500 Cr | Product-market fit, first revenue | Institutional VC thesis |
| Series B | ₹500–1,500 Cr | Unit economics, retention proof | Demonstrated scalability |
| Series C+ | ₹1,500–8,000 Cr | Market leadership, margin story | Revenue quality and governance |
| Pre-IPO | ₹8,000 Cr+ | IPO readiness, DRHP preparation | Listed peer comparables |
Each stage represents a real shift in business maturity, risk profile, and investor type, not just a bigger number on a term sheet.
Pre-IPO ████████████████████████████████████ ₹12,000 Cr
Series C+ ████████████████████████ ₹3,000 Cr
Series B ████████████████ ₹800 Cr
Series A ████████ ₹200 Cr
Seed ████ 20 Cr
The visual above is intentionally on a log scale. The jump from Seed to Series A looks similar to the jump from Series B to Series C, but in absolute rupee terms, the later jumps are vastly larger. This non-linear progression matters when evaluating whether a secondary market price makes sense relative to where the company actually sits in its journey.
When you buy shares in a listed company, you have an ocean of signals feeding into the price , quarterly earnings, analyst downgrades, management commentary, sector rotation. The price moves constantly because information moves constantly.
Unlisted shares have almost none of that. So what fills the vacuum? Funding rounds. When a credible group of institutional investors agrees on a valuation, that number becomes the primary reference point for everyone trading shares in the secondary market. It is the anchor until the next round drops.
What tends to get glossed over is that this signal is an opinion, not a measurement. Smart investors with rigorous processes have been catastrophically wrong about private company valuations.
A typical Series A company has a working product, early customers, and anecdotal evidence that people want what they are building. Revenue might exist, it is usually thin. Margins are not yet a real conversation.
What is actually being priced in a Series A round? The founder. The story. The market thesis. The belief, and it is a belief, not a conclusion, that this specific thing could become meaningful over the next several years.
In India, Series A valuations regularly run into hundreds of crores for companies that have not yet demonstrated they can sustain themselves financially. Rounds led by Sequoia India, Accel, and Elevation Capital across fintech, D2C consumer, and SaaS set reference prices in this range for pre-profitability businesses. Secondary buyers are paying for a thesis, not performance.
When a round like that closes, the secondary market reacts quickly. Shares that were available at one price become harder to source. Buyers who were watching from the sidelines either get in or accept that the entry point they wanted has passed.
The shift from Series A to Series B is a real shift, not just in size, but in what investors demand before they sign. The "great idea and a talented team" pitch no longer clears the bar for serious institutional money.
Investors at this stage want to see that growth is genuine. Are customers actually staying, or is retention inflated by promotional periods? Is the cost of acquiring new customers falling or rising as the company scales? When revenue doubled last year, was it because the model is becoming more efficient, or because headcount doubled at the same rate?
The post-2022 Indian startup landscape made Series B particularly scrutinised. Several startups raised large B rounds on inflated user numbers during the 2021–22 funding frenzy, only to face down-round corrections by 2023. Quick-commerce and edtech were both caught in this pattern. Investors now look beyond GMV and active-user counts, they want unit economics that hold up under pressure.
One trap worth naming: serial fundraising can create a convincing impression of momentum that has nothing to do with the business working. A company that has done A, then B, then is reportedly in C conversations looks like it is on a solid trajectory, sometimes it is. Sometimes each round was necessary because the previous capital ran out faster than expected.
Series C and beyond operate differently. By this point, a company is large enough that hand-waving about future potential does not satisfy investors writing the largest cheques. Gross margins get pulled apart. Revenue quality, how much is recurring versus one-time, becomes a genuine negotiating point. Governance starts to matter substantively, because weak board oversight creates expensive problems at the point of listing.
India's unicorn cohort tells the story plainly. Of the 100-plus companies that reached unicorn status between 2019 and 2023, only a fraction have converted that valuation into a credible public listing. Those that succeeded, Zomato, Nykaa, Delhivery, came with documented financials, functioning boards, and a clear revenue story. Those still waiting tend to share familiar characteristics: ongoing losses, governance questions, or market timing challenges they could not resolve.
This is the stage where things get genuinely complicated and where some of the most expensive mistakes are made. At Pre-IPO, pricing logic is based heavily on what the company will be worth once listed, introducing assumptions that are almost entirely outside anyone's control.
The Draft Red Herring Prospectus is the first concrete evidence that a company is genuinely preparing for a public listing, not just talking about it. Filed with SEBI, the DRHP covers audited financials for the last three years, risk factors and outstanding litigation, use of proceeds, promoter background and shareholding, related-party transactions, and the structure of the proposed offering.
For Pre-IPO secondary investors, the DRHP filing is one of the most important signals available. It tells you the company has engaged investment banks, Book Running Lead Managers or BRLMs, submitted to SEBI scrutiny, and is operating on a defined regulatory timeline. Shares traded after a DRHP filing are priced against a far more concrete picture than shares traded on IPO rumour.
Critical distinction: a filed DRHP is not an approved IPO. SEBI routinely issues observations requiring the company to address specific questions before listing can proceed. Several consumer tech companies withdrew DRHPs entirely when market conditions turned unfavourable in 2022.
Step 1 DRHP Filing with SEBI. The company files the draft prospectus with its BRLMs. Typical processing timeline is 30–75 days for SEBI observations, though complex cases extend further.
Step 2 SEBI Observation Letter. SEBI issues formal observations questions and required amendments the company must address before receiving no-objection to proceed.
Step 3 RHP Filing and Price Band Approval. The final Red Herring Prospectus is filed with the Registrar of Companies. The price band is determined and disclosed.
Step 4 Institutional Roadshows and Book-Building. Management meets QIBs, HNIs, and retail investors separately. QIB oversubscription is the most reliable indicator of post-listing performance.
Step 5 Allotment and Exchange Listing. SEBI approves allotment. BSE and NSE list the shares. The entire journey from DRHP filing to listing typically spans four to nine months in India, but can extend significantly.
Beyond regulatory filings, IPO readiness involves governance dimensions that matter enormously for post-listing performance. Listed companies face continuous disclosure obligations quarterly results within 45 days, material event disclosures within 24 hours, audit committee oversight, and annual shareholder meetings filed to the exchange.
Companies that strengthen governance before listing independent directors, Big Four-audited financials, internal financial controls certified under the Companies Act tend to list with less volatility. The contrast is visible between India's stronger listings and those that struggled immediately after listing.
In India's unlisted share ecosystem, the grey market premium is widely quoted in Pre-IPO discussions the premium above the issue price at which shares trade informally before listing. Honest assessment: GMP is useful but unreliable. It reflects retail appetite, not institutional demand, which is what actually determines QIB and HNI subscription quality. GMP has been significantly wrong in both directions. Treat it as one data point, not a return predictor.
When a funding announcement drops, the worst thing to do is react immediately. Work through these questions first.
Valuation versus business growth. If valuation is up 60% and revenue is up 20%, that gap needs a specific explanation sometimes it is just sentiment.
Investor quality. A fund with sector experience and a track record of successful exits is a meaningfully different signal than a round from investors you cannot readily verify.
Dilution math. A rising headline valuation with aggressive share issuance can still produce disappointing per-share outcomes.
Capital deployment. Capital going into markets with demonstrated demand is different from capital raised primarily to sustain current losses.
Pre-IPO specifics. Is the DRHP filed? Has SEBI issued observations? Who are the BRLMs? Is there a concrete timeline or just stated intent?
Treating institutional participation as a safety net. A fund investing at a high valuation may be comfortable because they hold positions from earlier, cheaper rounds. That math does not apply to a secondary buyer coming in fresh.
Not modelling dilution across multiple rounds. Investors calculate returns on a simple entry-to-exit valuation and skip the intervening rounds. By the time the exit happens, the dilution has eaten a significant chunk of the expected return.
Taking IPO timelines seriously. The distance between a stated IPO objective and an actual listing can span years. If your return thesis depends primarily on a specific IPO timeline, you are carrying more risk than you realise.
Confusing a filed DRHP with IPO certainty. A DRHP means a company is serious not that listing is imminent or guaranteed. Pre-IPO secondary prices sometimes do not adequately reflect this regulatory and timing uncertainty.
Supremus Angel works in the unlisted shares and Pre-IPO space, giving investors structured visibility into a part of the market that is genuinely difficult to navigate independently. Private companies are not subject to public disclosure requirements, which means investors routinely make decisions with a fraction of the information they would have when buying listed shares.
Supremus Angel addresses this gap by providing access to secondary market activity, funding histories, DRHP tracking, and Pre-IPO developments. The platform is informational and transactional not advisory. Independent due diligence and qualified advice remain essential before committing to any opportunity.
